IIDZUKA Yuzuru
   Department   School of Medicine, School of Medicine
   Position   Assistant Professor
Article types Original article
Language English
Peer review Peer reviewed
Title Protective effects of fish oil and pioglitazone on pancreatic tissue in obese KK mice with type 2 diabetes.
Journal Formal name:Prostaglandins, leukotrienes, and essential fatty acids
Abbreviation:Prostaglandins Leukot Essent Fatty Acids
ISSN code:15322823/09523278
Domestic / ForeginForegin
Volume, Issue, Page 115,pp.53-59
Author and coauthor Iizuka Yuzuru, Kim Hyounju, Izawa Takuya, Sakurai Koji, Hirako Satoshi, Wada Masahiro, Matsumoto Akiyo
Authorship Lead author
Publication date 2016/12
Summary n-3 Polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have protective effects against the pancreatic β-cell dysfunction through several mechanisms. Thiazolidines are insulin sensitizers and are used in treating patients with type 2 diabetes. Our previous study demonstrated that a combination of fish oil, which is rich with EPA and DHA, and pioglitazone exerts beneficial effects on obesity and diabetes through their actions on the liver and adipose tissue. However, it remains largely unknown whether such combination therapy affects the pancreas. To answer this question, KK mice, which serve as a model for obesity and type 2 diabetes, were treated for 8 weeks with fish oil and pioglitazone. The combined regimen suppressed pancreatic islet hypertrophy (mean islet area decreased by an average of 49% vs. control) compared with mice treated with fish oil or pioglitazone alone (decreased by an average of 21% and 32% vs. control, respectively). Compared with the controls, individual or combined treatment significantly increased the percentage of β-cell area in the pancreatic islets, significantly decreased endoplasmic reticulum stress, and reduced the percentage of apoptotic cell death in the pancreatic islets. These findings suggest that fish oil and/or pioglitazone prevents β-cell dysfunction by improving the insulin resistance and decreasing the ER stress.
DOI 10.1016/j.plefa.2016.10.007
PMID 27914514